NEW JERSEY LIFE SCIENCES + TECH ADVISORS
New Jersey, often referred to as “The Nation’s Medicine Chest”, is home to more than 3,200 life science and biopharma establishments, including 14 of the world’s top 20 pharmaceutical companies. Located in the densely populated and transit-connect Northeast Corridor, New Jersey’s robust pharma legacy thrives due to industry leaders such as Merck, Johnson & Johnson, Bristol Myers Squibb, Novartis, and Pfizer attracting a highly educated workforce. The state boasts the second-highest concentration of scientists and engineers in the U.S., and ranks third in employment of biochemists and biophysicists. Additionally, New Jersey offers ample second-generation lab space, providing an ideal environment for emerging bio-tech companies to flourish.
Cushman & Wakefield’s New Jersey Life Sciences & Tech Advisory team consists of local experts in the life sciences market. Our extensive global experience allow us to approach transactions with creativity and agility, ensuring a seamless process that saves time and reduces expenses. We specialize in aligning real estate strategies to business objectives, leveraging a profound understanding of labor markets, tax incentives, market dynamics, and the complexities of constructing specialized facilities.
The New Jersey Life Sciences & Tech Advisory team is a member of Cushman & Wakefield's National Life Sciences Practice Group. This globally diverse network delivers integrated solutions to investors, developers, and occupiers of life sciences real estate. Strategically positioned in major life sciences hub markets across the country, our experienced teams offer comprehensive coverage where innovation thrives. We build global connections, foster a culture of collaboration, and leverage cutting-edge data and research to meet our clients’ ever-evolving needs, wherever they want to be. With expertise in all areas of life sciences real estate, from site selection and lease negotiation to property and project management, we proudly partner with our clients in their mission to make the world a better place.
Cushman & Wakefield’s New Jersey Life Sciences & Tech Advisory team consists of local experts in the life sciences market. Our extensive global experience allow us to approach transactions with creativity and agility, ensuring a seamless process that saves time and reduces expenses. We specialize in aligning real estate strategies to business objectives, leveraging a profound understanding of labor markets, tax incentives, market dynamics, and the complexities of constructing specialized facilities.
The New Jersey Life Sciences & Tech Advisory team is a member of Cushman & Wakefield's National Life Sciences Practice Group. This globally diverse network delivers integrated solutions to investors, developers, and occupiers of life sciences real estate. Strategically positioned in major life sciences hub markets across the country, our experienced teams offer comprehensive coverage where innovation thrives. We build global connections, foster a culture of collaboration, and leverage cutting-edge data and research to meet our clients’ ever-evolving needs, wherever they want to be. With expertise in all areas of life sciences real estate, from site selection and lease negotiation to property and project management, we proudly partner with our clients in their mission to make the world a better place.
Meet the Advisory Team
Meet the PDS Team
Meet the V & A Team
Recent Tenant Advisory Transactions
2 Clarke Drive
Property Address: 2 Clarke Drive, Cranbury, NJ
Size: 72,000 SF
Size: 72,000 SF
270 Prospect Plains Road
Property Address: 270 Prospect Plains Road, Cranbury, NJ
Size: 223,936 SF
Client: CMIC
Size: 223,936 SF
Client: CMIC
311 Pennington Rocky Hill Road
Property Address: 311 Pennington Rocky Hill Road, Hopewell Township, NJ
Size: 223,000 SF
Client: PTC Therapeutics
Size: 223,000 SF
Client: PTC Therapeutics
Related Insights
Research
Life Sciences Fit Out Cost Guide
Our 2025 Life Sciences Fit Out Cost Guide covers five lab types, two cGMP types, warehouse and office across the six major U.S. life sciences markets.
Brian Ungles • 11/1/2024
Research
Cushman & Wakefield’s 2024 life sciences market report covers national trends and dive deep into top global life sciences markets, for an in-depth look at this quickly changing industry.
Sandy Romero • 9/17/2024
Research
Life Sciences Funding in View
Global life sciences venture capital funding has reverted to its pre-pandemic long-term trend.
Sandy Romero • 1/29/2024
Research
Recent Ups and Downs for the Life Sciences Market
Life sciences tenants searching for space is up over 22% since late spring with activity in real estate grew as well, with over 31 million square feet (sf) of lab and cGMP space leased from 2021 to 2022.
Sandy Romero • 11/8/2023
Article
Does your building qualify for a life sciences conversion?
Interest in converting assets for life sciences use is growing amongst building owners. Cushman & Wakefield’s Project & Development Services team developed basic building performance criteria based on the minimum standards that life sciences companies typically require.
Eric Giles • 7/18/2023
Article
Challenges for Life Sciences Projects Means Early Engagement of Project Managers
Persistent challenges continue to impact costs, material lead times and project timelines across all life sciences projects.
Jason D'Orlando • 6/30/2023